ELOX.US Eloxx Pharmaceuticals, Inc.

Healthcare Biotechnology USA Stocks
13.15 USD
Close of Nov 14, 2026
8.20 23.40
Market cap
USD 53.1M
P/E
3.7x
P/B
1.13x
ROE
-35.6%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is ELOX.US undervalued?

Graham number
Price13.15
Graham value30.35
Discount56.7%

ELOX.US trades 56.7% below its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Eloxx Pharmaceuticals, Inc. fundamental analysis

No fundamental analysis for Eloxx Pharmaceuticals, Inc. yet.

Eloxx Pharmaceuticals, Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Eloxx Pharmaceuticals, Inc.

Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates that modulate the ribosome and promote readthrough of premature stop codons caused by nonsense mutations in the United States, Israel, and Australia. The company is developing exaluren, a eukaryotic ribosome-selective glycoside in a Phase 2 trial for the treatment of rare kidney diseases, including Alport syndrome with nonsense mutations, cystic fibrosis with n…

Full company profile